2-[3-(3-methylphenyl)ureido]acetic acid | 133115-37-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[3-(3-methylphenyl)ureido]acetic acid
• 英文别名: (3-m-tolylureido)acetic acid；2-(3-m-tolyl-ureido)acetic acid；2-{[(3-Methylphenyl)carbamoyl]amino}acetic acid；2-[(3-methylphenyl)carbamoylamino]acetic acid
• CAS: 133115-37-4
• 化学式: C₁₀H₁₂N₂O₃
• mdl: MFCD08444862
• 分子量: 208.217
• InChiKey: VZOMJJJMNAGVRE-UHFFFAOYSA-N

物化性质

• 沸点：
  379.6±42.0 °C(Predicted)
• 密度：
  1.311±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[3-(3-methylphenyl)ureido]acetic acid 、 (2S,5R)-tert-butyl 5-phenylprolinate 在 N-甲基吗啉 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 以74%的产率得到(2S,5R)-tert-butyl 1-<2-<3-(3-methylphenyl)-ureido>-1-oxo-ethyl>-5-phenyl-pyrrolidine-2-carboxylate
  参考文献：
  名称：

  Application of asymmetric phase-transfer catalysis in the enantioselective synthesis of cis-5-substituted proline esters

  摘要：

  A simple, highly stereoselective three-step sequence for the enantioselective synthesis of cis-5-substituted praline esters is described. This sequence features an asymmetric PTC Michael addition, followed by acid catalysed imine exchange and catalytic hydrogenation. Application of this chemistry in the synthesis of the nonpeptide cholecystokinin antagonist (+)-RP-66803 11 is also described. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2010.09.075
• 作为产物：
  描述：

  N,N-二甲基丙烯酰胺 、 tert-butyl benzylideneaminoacetate 在 silver(I) acetate 、 三乙胺 作用下， 以 乙腈 为溶剂， 生成 2-[3-(3-methylphenyl)ureido]acetic acid 、 tert-butyl (2RS,4RS,5SR)-4-dimethylcarbamoyl-5-phenylpyrrolidine-2-carboxylate
  参考文献：
  名称：

  N-acylpyrrolidines and medicaments for the treatment or prevention of

  摘要：

  本发明涉及公式的衍生物：##STR1##及其盐，其制备方法以及含有它们的药物。

  公开号：

  US05707991A1

文献信息

• Pyrrolidine and thiazolidine derivatives, their preparation and
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05610144A1

  公开（公告）日：1997-03-11

  This invention relates to compositions of formula: ##STR1## and their salts, their preparation and the medicaments containing them.

  这项发明涉及以下结构的化合物：##STR1##及其盐，它们的制备以及含有它们的药物。
• N-phenyl-N-acetamidoglycinamides, their preparation and medicaments
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05382590A1

  公开（公告）日：1995-01-17

  Compounds of formula: ##STR1## in which R.sub.1 represents a hydrogen atom or an alkyl, alkoxycarbonyl or an unsubstituted or substituted phenyl radical, R.sub.2 represents a hydrogen atom or an unsubstituted or substituted alkyl radical, R.sub.3 represents an alkyl, phenylalkyl, indanyl, cycloalkylalkyl or an unsubstituted or substituted phenyl radical, or R.sub.2 and R.sub.3 form a heterocycle together with the nitrogen atom to which they are attached, and R.sub.4 represents an unsubstituted or substituted phenyl radical, a naphthyl, indolyl or quinolyl radical or a phenylamino radical in which the phenyl ring is unsubstituted or substituted, their preparation and medicaments containing them.

  公式为：##STR1##，其中R.sub.1代表氢原子或烷基、烷氧羰基或未取代或取代的苯基基团，R.sub.2代表氢原子或未取代或取代的烷基基团，R.sub.3代表烷基、苯基烷基、茚基、环烷基烷基或未取代或取代的苯基基团，或R.sub.2和R.sub.3与它们连接的氮原子一起形成一个杂环，R.sub.4代表未取代或取代的苯基基团、萘基、吲哚基或喹啉基团或苯胺基团，其中苯环未取代或取代，它们的制备以及含有它们的药物。
• N-phenyl-n-alkoxycarbonylalkyl glycinamides, their preparation and the
  申请人：Rhone-Poulenc Rorer, S.A.

  公开号：US05374656A1

  公开（公告）日：1994-12-20

  This invention relates to compounds of formula: ##STR1## in which R.sub.1 represents a hydrogen atom or an alkyl or alkoxycarbonyl radical or an unsubstituted or substituted phenyl radical, R.sub.2 represents an alkyl (1-8 C) or polyfluoroalkyl radical or an unsubstituted or substituted cycloalkyl radical, R.sub.3 represents an unsubstituted or substituted phenyl radical, a naphthyl, indolyl, quinolyl or phenylamino radical in which the phenyl ring is optionally substituted, or a quinolylamino radical, and m is 0 or 1, the process for preparing them and the medicaments containing them.

  本发明涉及以下结构式的化合物：##STR1## 其中R.sub.1代表氢原子或烷基或烷氧基羰基基团或未取代或取代的苯基基团，R.sub.2代表烷基（1-8 C）或多氟烷基基团或未取代或取代的环烷基基团，R.sub.3代表未取代或取代的苯基基团，萘基，吲哚基，喹啉基或苯胺基基团，其中苯环可选取代，或喹啉胺基基团，m为0或1，以及制备它们和含有它们的药物的过程。
• N-phenylamides and medicinal products containing them
  申请人：Rhone-Poulenc Sante

  公开号：US05223529A1

  公开（公告）日：1993-06-29

  Compounds of formula: ##STR1## in which R.sub.1 is (a) a phenyl radical or a substituted phenyl radical, (b) a chain --CH(R.sub.8)--COOR.sub.4, (c) a chain --CH.sub.2 --CO--NR.sub.5 R.sub.6 or (d) a phenylalkyl radical, R.sub.2 is a methylene or ethylene radical or a radical --CH(R.sub.7)--, R.sub.3 is a 1- or 2-naphthyl radical, 2- or 3-indolyl or phenylamino radical in which the phenyl ring is optionally substituted on the understanding that, when R.sub.3 is 1- or 2-naphthyl or 2- or 3-indolyl radical, R.sub.7 cannot represent a benzyl, alkylthioalkyl or phenyl radical, as well as, when R.sub.2 is a radical --CH(R.sub.7)--, their racemates and their stereoisomers, and medicinal products containing them.

  式为##STR1##的化合物，其中R.sub.1是(a)苯基或取代苯基，(b)链--CH(R.sub.8)--COOR.sub.4，(c)链--CH.sub.2--CO--NR.sub.5 R.sub.6或(d)苯基烷基基团，R.sub.2是亚甲基或乙烯基或基团--CH(R.sub.7)--，R.sub.3是1-或2-萘基基团，2-或3-吲哚基或苯基氨基基团，其中苯环可选地取代，当R.sub.3是1-或2-萘基或2-或3-吲哚基团时，R.sub.7不能表示苄基、烷基硫代烷基或苯基基团，以及当R.sub.2是基团--CH(R.sub.7)--时，它们的外消旋体和立体异构体，以及含有它们的药物制剂。
• N-phenylglycinamide CCK antagonists and pharmaceutical compositions
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05475106A1

  公开（公告）日：1995-12-12

  Compounds of formula: ##STR1## in which R.sub.1 represents a hydrogen atom, an alkyl or alkoxycarbonyl radical or a phenyl radical, optionally substituted, R.sub.2 represents an alkoxy, optionally substituted cycloalkyloxy, cycloalkylalkyloxy, phenylalkyloxy, polyfluoroalkyloxy or cinnamyloxy radical or a radical --NR.sub.5 R.sub.6, R.sub.3 represents a phenylamino radical in which the phenyl ring is optionally substituted, an optionally substituted phenyl radical or a naphthyl, indolyl or quinolyl radical, R.sub.4 represents a substituted phenyl radical, R.sub.5 and R.sub.6, which may be identical or different, represent a hydrogen atom or an alkyl, optionally substituted phenyl, indanyl, cycloalkylalkyl, cycloalkyl or phenylalkyl radical, or alternatively R.sub.5 and R.sub.6, together with the nitrogen atom to which they are attached, form a heterocycle, their preparation and medicinal products containing them.

  化合物的公式：##STR1## 其中R.sub.1代表氢原子，烷基或烷氧羰基基团或苯基，可选地取代；R.sub.2代表烷氧基，可选地取代的环烷氧基，环烷基烷氧基，苯基烷氧基，多氟烷基氧基或肉桂氧基基团或基团--NR.sub.5 R.sub.6，R.sub.3代表苯基氨基基团，其中苯环可选地取代，可选地取代的苯基基团或萘基，吲哚基或喹啉基，R.sub.4代表取代的苯基基团，R.sub.5和R.sub.6，可以相同也可以不同，代表氢原子或烷基，可选地取代的苯基，吲哚基，环烷基烷基，环烷基或苯基烷基基团，或者R.sub.5和R.sub.6与它们连接的氮原子一起形成杂环，它们的制备和含有它们的药物产品。